Recent Updates
Recently added Catalysts
CGEN Positive Sentiment Score: 70/100

Compugen to Present at the JMP Securities Life Sciences Conference

Tuesday, May 9, 2023 2 min read
Key Takeaway: Compugen Ltd. (CGEN) announced its management will present at the JMP Securities Life Sciences Conference on May 16, 2023. The virtual presentation highlights the company's ongoing efforts in cancer immunotherapy and its proprietary product candidates. Compugen has developed notable therapies such as COM701 and COM902, along with a partnered program, rilvegostomig, currently in Phase 2. The webcast of the presentation will be available on their Investor Relations website, underscoring their commitment to investor engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Compugen will present at the JMP Securities Life Sciences Conference, increasing visibility.
  • The company is advancing multiple promising therapeutic candidates for cancer treatment.
  • Live webcast and replay availability demonstrates commitment to transparent investor communications.

Full Press Release Details

HOLON, Israel, May 9, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the JMP Securities Life Sciences Conference (virtually), on Tuesday, May 16, 2023 at 9:00 AM ET.
A live webcast of the presentation will be available on the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event for 90 days.
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2 development by AstraZeneca through a license agreement for the development of bi-specific and multi-specific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The most advanced program, COM503 in IND enabling studies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 to inhibit cancer growth in the tumor microenvironment. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: [email protected]
Tel: +1 (628) 241-0071
SOURCE Compugen Ltd.

21 %

more press release views with

Frequently Asked Questions

What event will Compugen present at on May 16, 2023?

Compugen will present virtually at the JMP Securities Life Sciences Conference.

How can I watch Compugen's presentation online?

The presentation will be available via a live webcast on Compugen's Investor Relations page.

What are Compugen's key product candidates?

Compugen's key candidates include COM701 and COM902, targeting cancer therapies.

What are the main programs in Compugen's pipeline?

Compugen's pipeline includes programs targeting immune resistance in cancer.

Where is Compugen headquartered?

Compugen is headquartered in Holon, Israel, with an office in San Francisco.

Tags: CGEN Viatris Investor Conferences Healthcare cancer immunotherapy JMP Securities clinical stage therapeutic candidates
Last updated: May 9, 2023